Physician profile
Robert W Ledbetter
NPI 1649224130
$5,641.50
in general payments reported to CMS, 2019-2025
20 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $512 · 2021: $991 · 2022: $689 · 2023: $582 · 2024: $597 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624 · Travel and Lodging: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.55 |
| Travel and Lodging | $824.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,371.22 | 2019-2025 | Ingevity+, Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.32 | 2020-2025 | Lifevest |
| Abbott Laboratories | $153.00 | 2020 | |
| Angiodynamics, INC. | $147.63 | 2021 | |
| Pfizer INC. | $144.42 | 2022-2025 | |
| Corindus INC. | $117.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $100.00 | 2022 | |
| Medtronic, INC. | $86.83 | 2021 | |
| Medtronic Vascular, INC. | $59.40 | 2019-2020 | |
| Abiomed | $41.63 | 2024 | Impella |
| Opsens INC. | $40.72 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $39.40 | 2024 | Farxiga |
| Endologix LLC | $34.38 | 2019 | |
| Scpharmaceuticals INC. | $25.41 | 2023 | |
| Novo Nordisk INC | $23.27 | 2024 | Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $21.29 | 2024 | Zio Xt Patch, Zio Monitor |
| Banner Life Sciences, LLC | $18.82 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.21 | 2025 | |
| Amgen INC. | $17.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ledbetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.